whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. SOURCE AbelZeta Pharma, Inc. The articles, information, and content ...

Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether ...

Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals, said:"We are thrilled to see bexmarilimab's data receive acceptance for oral presentation at EHA, following similar recognition at MDS and ASCO.

have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant ...

Oral history adviser Lynette Shum will speak in Gisborne on May 21 about the SS Ventnor Legacy and will host an oral history workshop the following day. Alexander Turnbull Library oral history ...

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg ...

in an oral presentation and a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. The presentations ...

How can you use royalty-free images and video clips? From social media ads to billboards, PowerPoint presentations to feature films, you're free to modify, resize and customize every asset on iStock — ...

SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...